GeneDx Q1 Earnings Call Highlights

Key Points

• Volume growth but revenue shortfall: Exome and genome volume rose 34% (27,488 tests) yet total revenue missed by about $12M, with reported revenue of $102.3M and a blended ARR of ~$3,300 (roughly $200 below expectations) due to a mix shift toward genomes (≈40% of outpatient volume) and weaker non‑core lines.
• Cost cuts and lowered guidance while targeting profitability: Management is cutting $25M of planned OpEx and trimmed full‑year guidance by ~12% (~$65M at the midpoint) to $475–$490M, while still forecasting ≥30% exome/genome volume growth and expecting adjusted profitability for 2026 with a return to profitability in Q3.

GeneDx NASDAQ: WGS reported first-quarter 2026 results showing continued growth in exome and genome testing volumes, but lower-than-expected revenue as a shift in product mix pressured reimbursement rates and several non-core business lines underperformed.

Q1 results: Volume up 34% as revenue missed expectations

Chief Executive Officer Katherine Stueland said exome and genome volume grew 34% year-over-year in the first quarter, driven by demand in the company’s “foundational markets” and early momentum in expansion markets. However, she said total revenue came in “$12 million lower than expected,” prompting a channel-by-channel review and a reduction to full-year guidance.

Chief Financial Officer Kevin Feeley reported total revenue of $102.3 million, including $90.6 million of exome and genome revenue (up 27%), on 27,488 exome and genome test results (up 34%). The company’s blended average reimbursement rate (ARR) was approximately $3,300, adjusted gross margin was 69%, and GeneDx posted an adjusted net loss of $8.2 million.

What drove the revenue shortfall

Stueland said the $12 million revenue shortfall was driven by two factors:

• ~$5.5 million from a lower-than-expected blended average reimbursement rate for exome and genome
• ~$6.5 million from softer-than-expected performance in non-core business lines

Feeley said the blended ARR came in about $200 below expectations, but emphasized that “on a like-for-like basis, ARR by product is relatively unchanged,” citing no meaningful contracted price changes and no material changes in coverage or collection rates within each channel. Instead, he attributed the decline primarily to product mix shifts within the exome and genome portfolio.

Feeley said roughly 85% of volume is insurance-based outpatient testing and 15% is institutional pay. In outpatient testing, genome represented about 40% of Q1 volume—“roughly double from a year ago,” he said. Feeley added that an outpatient exome is closer to a blended average of about $4,000 per test after denials, while an outpatient genome blended ARR is “about half that of exome” due to less mature payer coverage. He also said parental comparator mix impacted the blended ARR during the quarter.

On the non-core lines, Feeley said Fabric missed by about $2.5 million, which he attributed to “legacy positioning and its go-to-market approach.” He also noted that GAAP financials included a non-cash impairment charge of approximately $31.3 million tied to goodwill and certain intangibles. Biopharma and data missed by about $2 million due to a longer sales cycle, and multi-gene panels missed by about $2 million due to overestimating the timing of “organic CMA uptake” in pediatrics.

Strategy update: Managing the transition to genome and focusing on core diagnostics

Stueland said the company sees accelerating demand for genome among geneticists and described the shift as faster than expected. She said the company launched a reflex offering in February aimed at balancing clinical demand with “a relatively higher gross margin product,” with positive early customer feedback.

Feeley described the reflex product as “a tool to manage the transition in the geneticist office only,” while noting that genome remains a “good margin test” even though exome has a higher gross margin and the reflex offering sits between them.

Stueland also said GeneDx is fully integrating the Fabric Genomics team, technology, and services into the GeneDx brand and refocusing Fabric’s interpretation-as-a-service offering toward international markets, lowering expectations for its 2026 revenue contribution accordingly. On the biopharma and data business, she cited “positive underlying momentum,” but said Q1 revenue fell short due to longer-than-anticipated sales cycles; she added that GeneDx has “right-sized” 2026 expectations to include only high-probability deals, treating the segment as upside as it ramps.

Cost actions and 2026 guidance revised lower

Stueland said the company is taking “the decisive step of cutting $25 million of OpEx for the year” and prioritizing three “biggest levers”:

• Growing utilization of exome and genome
• Optimizing unit economics through ARR and cost of goods sold (COGS)
• Delivering products at scale

Feeley said the $25 million represents “a reduction in future planned increases” rather than cuts from the current run rate, primarily by slowing hiring and marketing timing while protecting investments in proven channels and “line-of-sight expansion markets.”

Management reduced full-year revenue guidance by 12% (or $65 million at the midpoint). Feeley said the bridge included $36 million from blended ARR effects, $11 million from lower volume contribution across new expansion markets, and $18 million from non-core business lines split evenly between Fabric, biopharma, and other testing.

Updated full-year 2026 guidance calls for:

• Total revenue: $475 million to $490 million
• Exome and genome volume growth: at least 30% (approximately 126,400 tests)
• Exome and genome revenue growth: at least 20%
• Adjusted gross margin: approximately 70%
• Adjusted profitability for the full year

For the second quarter, the company guided to $110 million to $112 million in total revenue, about 30,000 exome and genome tests, approximately $100 million of exome and genome revenue, adjusted gross margin of about 70%, and an adjusted net loss of approximately $5 million, with Feeley saying GeneDx expects to return to profitability in the third quarter.

Q&A: Visibility, salesforce buildout, and reimbursement outlook

During the question-and-answer session, analysts pressed management on visibility into the revised outlook and the reimbursement trajectory for genome testing.

Feeley said the mix shift “began to crystallize at the tail end of March,” and that the company has since reset assumptions “channel by channel.” Stueland said Q2 guidance reflects “momentum that we’re seeing in terms of volumes coming in for the quarter” and described traction in the NICU as improving following expansion of the sales force.

On the commercial footprint, Stueland said GeneDx now has four sales teams: 75 people selling to specialists (about 25 new), 50 reps in general pediatrics, and 10 reps each in NICU and prenatal, calling several of these channels “early days” for understanding full productivity.

On reimbursement, Feeley said genome ARR could move “towards parity with exome” over time, citing opportunities to expand commercial coverage, improve documentation and claims processes, and reduce denials through automation. He also pointed to clinical and economic evidence, including the SAVES-Kids study, which he said found GeneDx testing could lead to “cost savings of up to $80,000 in the first year after testing” for children with neurodevelopmental disorders. Feeley also noted that “across state Medicaid programs, there are now 38 states covering either test.”

Stueland said GeneDx is working on long-read whole genome sequencing, noting it has been offered in a research setting for some clients and would be available “at some point in a commercially available product as well.” She also said the company has not seen a change in competitive dynamics.

About GeneDx NASDAQ: WGS

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.